|1.||D'Alessandro, R: 2 articles (01/2008 - 01/2005)|
|2.||Candelise, L: 2 articles (01/2008 - 01/2005)|
|3.||Vignatelli, L: 2 articles (01/2008 - 01/2005)|
01/01/2005 - "In the first trial (10 participants) femoxetine had no significant effect in eliminating or reducing EDS; a significant reduction of cataplexy was in favour of femoxetine. "
01/01/2008 - "In one cross-over trial (10 participants) femoxetine had no significant effect in eliminating or reducing EDS but significantly reduced cataplexy. "
10/01/1986 - "The side-effects of femoxetine were restricted to transient nausea in 2 patients. "
09/01/1986 - "Nausea was the side effect most commonly reported by patients treated with femoxetine, whereas a significantly greater frequency of anticholinergic side effects was recorded during treatment with amitriptyline (P less than 0.05). "
03/01/1983 - "Femoxetine led to transitory nausea and gastrointestinal discomfort, but in contrast to doxepin, no weight gain and only slight, if any, sedation. "
|3.||Migraine Disorders (Migraine)
09/01/1986 - "This supports earlier studies that femoxetine generally exerts no prophylactic effect on migraine, and the hypothesis that platelet 5HT might be of major importance in the pathogenesis of migraine is not supported."
09/01/1986 - "A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine."
08/01/1982 - "Unlike most drugs used in migraine prophylaxis, femoxetine did not influence platelet aggregation in vitro. "
12/01/1981 - "These results indicate that femoxetine could be useful in migraine as a prophylactic drug."
12/01/1981 - "The prophylactic effect in migraine of femoxetine, a 5-HT-uptake inhibitor, was compared to that of placebo in a double-blind group-comparative study. "
09/01/1986 - "No effect of femoxetine could be demonstrated in attack frequency and headache index. "
10/01/1983 - "In the 24 patients who continued the study to the end, the periods of propranolol (administered 160 mg daily) and of femoxetine (given 400 mg daily) differed significantly from each other with respect to the attack frequency and headache index. "
10/01/1981 - "In the 37 patients who completed the trial there was no significant difference between propranolol 160 mg and femoxetine 400 mg with respect to the number of headache days or the number of migraine attacks during the last 2 months of each treatment, Propranolol, however, was superior to femoxetine when the headache index was used (P less than 0.05). "
03/01/1983 - "Sixteen patients with a headache resembling the so-called "tension headache" and a clear response to doxepin (demonstrated in a previous work) were given femoxetine, 400 mg p.d., and placebo in a cross-over, double-blind fashion. "
10/01/1986 - "A randomized, double-blind cross-over trial was carried out in 10 patients with narcolepsy to evaluate the effect of 600 mg femoxetine versus placebo. "
10/01/1986 - "The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo."
|3.||Serotonin (5 Hydroxytryptamine)
|4.||Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)
|10.||5-Hydroxytryptophan (5 Hydroxytryptophan)